search
Back to results

A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)

Primary Purpose

Chronic Kidney Disease (CKD)

Status
Completed
Phase
Not Applicable
Locations
Paraguay
Study Type
Interventional
Intervention
Endovasccular AVF (EndoAVF)
Sponsored by
TVA Medical Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Kidney Disease (CKD) focused on measuring Chronic kidney disease, Arteriovenous fistula, Hemodialysis, Vascular access

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Eligible for a native surgical arteriovenous fistula, as determined by the treating physician.
  • Adult (age >18 years old).
  • Advanced chronic kidney disease (CKD), stage 4 or 5 electing for hemodialysis.
  • Written informed consent obtained

Sites / Locations

  • Italian Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Endovascular AVF (EndoAVF)

Arm Description

The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access

Outcomes

Primary Outcome Measures

Adverse Events
The safety of the FLEX-1 system based on the overall complication rates derived from adverse event data.

Secondary Outcome Measures

Access Functionality
The functionality of the AVF will be measured based on use of the AVF with two needles for at least 75% of dialysis sessions over a 4-week period following at least a one month maturation period.

Full Information

First Posted
April 17, 2014
Last Updated
April 21, 2014
Sponsor
TVA Medical Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02119832
Brief Title
A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)
Official Title
A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction
Study Type
Interventional

2. Study Status

Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TVA Medical Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this clinical study is to evaluate the preliminary safety and effectiveness of using the FLEX-1 device for the creation of an arteriovenous fistula (AVF) including coiling of the brachial vein during the index procedure in patients requiring chronic hemodialysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Disease (CKD)
Keywords
Chronic kidney disease, Arteriovenous fistula, Hemodialysis, Vascular access

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Endovascular AVF (EndoAVF)
Arm Type
Experimental
Arm Description
The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
Intervention Type
Device
Intervention Name(s)
Endovasccular AVF (EndoAVF)
Other Intervention Name(s)
FLEX
Intervention Description
The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
Primary Outcome Measure Information:
Title
Adverse Events
Description
The safety of the FLEX-1 system based on the overall complication rates derived from adverse event data.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Access Functionality
Description
The functionality of the AVF will be measured based on use of the AVF with two needles for at least 75% of dialysis sessions over a 4-week period following at least a one month maturation period.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Eligible for a native surgical arteriovenous fistula, as determined by the treating physician. Adult (age >18 years old). Advanced chronic kidney disease (CKD), stage 4 or 5 electing for hemodialysis. Written informed consent obtained
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adrian Ebner, MD
Organizational Affiliation
Italian Hosptial, Asuncion, Paraguay
Official's Role
Principal Investigator
Facility Information:
Facility Name
Italian Hospital
City
Asuncion
ZIP/Postal Code
1001-1925
Country
Paraguay

12. IPD Sharing Statement

Learn more about this trial

A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)

We'll reach out to this number within 24 hrs